BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts assign BioCryst a “Moderate Buy” consensus: Seven of 12 covering firms rate the stock a buy, while five recommend holding it. The average 12-month price target is $20.40.
• BioCryst reported quarterly EPS of $0.30, exceeding the $0.15 consensus estimate, while revenue rose 33.6% year over year to $218.25 million. However, analysts expect a full-year loss of $2.25 per share.
• Shares opened at $8.23, near the lower end of their $6.00–$11.22 one-year range, and institutional investors and hedge funds own 85.88% of the stock.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the twelve brokerages that are covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $20.40.

A number of research firms have recently issued reports on BCRX. HC Wainwright reaffirmed a "buy" rating and set a $32.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, June 30th. Cantor Fitzgerald raised their price objective on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an "overweight" rating in a research report on Tuesday, June 30th. Weiss Ratings restated a "hold (c)" rating on shares of BioCryst Pharmaceuticals in a research note on Thursday, August 27th. Needham & Company LLC reissued a "buy" rating and issued a $16.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, September 8th. Finally, Royal Bank Of Canada downgraded BioCryst Pharmaceuticals from an "outperform" rating to a "sector perform" rating and cut their price target for the stock from $13.00 to $11.00 in a report on Thursday, September 10th.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ:BCRX opened at $8.23 on Tuesday. The business's 50 day moving average price is $9.61 and its 200-day moving average price is $9.24. BioCryst Pharmaceuticals has a 1 year low of $6.00 and a 1 year high of $11.22. The firm has a market capitalization of $2.10 billion, a price-to-earnings ratio of -5.49 and a beta of 0.57.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 EPS for the quarter, topping analysts' consensus estimates of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The business had revenue of $218.25 million during the quarter, compared to analysts' expectations of $183.28 million. During the same quarter in the previous year, the company earned $0.15 earnings per share. The company's quarterly revenue was up 33.6% on a year-over-year basis. On average, sell-side analysts expect that BioCryst Pharmaceuticals will post -2.25 earnings per share for the current year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Large investors have recently modified their holdings of the company. WINTON GROUP Ltd raised its holdings in BioCryst Pharmaceuticals by 380.3% during the second quarter. WINTON GROUP Ltd now owns 255,600 shares of the biotechnology company's stock worth $2,556,000 after purchasing an additional 202,384 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new stake in BioCryst Pharmaceuticals in the second quarter valued at about $108,000. IFP Advisors Inc boosted its holdings in BioCryst Pharmaceuticals by 2,515.3% in the 2nd quarter. IFP Advisors Inc now owns 3,243 shares of the biotechnology company's stock valued at $32,000 after purchasing an additional 3,119 shares in the last quarter. Squarepoint Ops LLC boosted its holdings in BioCryst Pharmaceuticals by 339.4% in the 2nd quarter. Squarepoint Ops LLC now owns 174,714 shares of the biotechnology company's stock valued at $1,747,000 after purchasing an additional 134,949 shares in the last quarter. Finally, Allworth Financial LP increased its position in BioCryst Pharmaceuticals by 984.3% during the 2nd quarter. Allworth Financial LP now owns 5,172 shares of the biotechnology company's stock worth $52,000 after purchasing an additional 4,695 shares during the period. 85.88% of the stock is owned by institutional investors and hedge funds.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes orally administered medicines for rare diseases. The company focuses on treatments that address significant unmet medical needs, using expertise in small-molecule drug discovery and development.

BioCryst's primary commercial product is ORLADEYO (berotralstat), an oral, once-daily medication used to prevent hereditary angioedema attacks in adults and pediatric patients ages 12 and older.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.